GlassScriptPhysician profile
Rejo Cherian
NPI 1134567118
$9,021.44
in general payments reported to CMS, 2019-2025
57 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $930 · 2021: $713 · 2022: $1,573 · 2023: $1,826 · 2024: $1,351 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,257.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,339.63 | 2019-2025 | Botox, Ubrelvy, Duopa |
| Ge Healthcare | $756.06 | 2019-2025 | |
| Argenx US, INC. | $622.48 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acorda Therapeutics, INC | $510.84 | 2019-2024 | Inbrija |
| Alexion Pharmaceuticals, INC. | $452.67 | 2019-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $390.17 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $333.06 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $321.49 | 2019-2025 | Firdapse |
| Takeda Pharmaceuticals U.S.A., INC. | $252.81 | 2021-2024 | Gammagard, Hyqvia |
| Ucb, INC. | $249.76 | 2021-2025 | Fintepla, Rystiggo, Zilbrysq |
| Amneal Pharmaceuticals LLC | $217.46 | 2019-2024 | Rytary |
| Acadia Pharmaceuticals INC | $215.20 | 2019-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $177.04 | 2019-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $176.55 | 2019-2020 | |
| Allergan, INC. | $163.31 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rejo Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.